PremiumPre-EarningsAPLT Earnings Report this Week: Is It a Buy, Ahead of Earnings? APLT Lawsuit Alert! Class Action Against Applied Therapeutics, Inc. Applied Therapeutics appoints Colacot as VP, Head of Quality PremiumThe FlyApplied Therapeutics downgraded to Market Perform from Outperform at William Blair Applied Therapeutics price target lowered to $1.50 from $4 at RBC Capital Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles PremiumThe FlyApplied Therapeutics downgraded to Neutral from Buy at UBS Applied Therapeutics price target lowered to $5 from $14 at Baird Applied Therapeutics (APLT) Stock Plunges 75% as FDA Rules Against Genetic Drug 
